Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Short-Term Debt issuances (2017 - 2021)

Ani Pharmaceuticals (ANIP) has disclosed Short-Term Debt issuances for 5 consecutive years, with $262.0 million as the latest value for Q4 2021.

  • Quarterly Short-Term Debt issuances rose 1846.88% to $262.0 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $286.0 million through Dec 2021, changed N/A year-over-year, with the annual reading at $286.0 million for FY2021, N/A changed from the prior year.
  • Short-Term Debt issuances hit $262.0 million in Q4 2021 for Ani Pharmaceuticals, up from $24.0 million in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $262.0 million in Q4 2021 to a low of -$15.0 million in Q4 2020.
  • Historically, Short-Term Debt issuances has averaged $51.8 million across 3 years, with a median of $19.5 million in 2020.
  • Biggest YoY gain for Short-Term Debt issuances was 1846.88% in 2021; the steepest drop was 1846.88% in 2021.
  • Year by year, Short-Term Debt issuances stood at -$5.0 million in 2017, then crashed by 200.0% to -$15.0 million in 2020, then soared by 1846.88% to $262.0 million in 2021.
  • Business Quant data shows Short-Term Debt issuances for ANIP at $262.0 million in Q4 2021, $24.0 million in Q2 2021, and -$15.0 million in Q4 2020.